GlassScriptPhysician profile
Anna Lucy Sobol
NPI 1386627677
$1,901.77
in general payments reported to CMS, 2019-2025
29 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $248 · 2021: $316 · 2022: $268 · 2023: $101 · 2024: $201 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412 · Education: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.77 |
| Education | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $173.75 | 2019-2023 | Darzalex, Imbruvica, Talvey |
| Pfizer INC. | $148.96 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $143.47 | 2019-2022 | |
| Genentech USA, INC. | $134.17 | 2019-2020 | |
| Celgene Corporation | $131.44 | 2019-2024 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $129.23 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $126.97 | 2020-2025 | Enhertu |
| Amgen INC. | $124.12 | 2019-2020 | |
| Foundation Medicine, INC. | $95.60 | 2021-2023 | |
| Tesaro, INC. | $75.23 | 2019 | |
| Fennec Pharmaceuticals, INC. | $68.45 | 2024-2025 | Fyarro, Pedmark |
| Novartis Pharmaceuticals Corporation | $67.70 | 2019 | |
| Merck Sharp & Dohme LLC | $56.75 | 2020-2022 | |
| Gilead Sciences, INC. | $47.21 | 2019-2022 | |
| Array Biopharma INC | $43.76 | 2020-2023 | Braftovi, Lorbrena, Mektovi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $35.49 | 2020-2021 | |
| Epizyme, INC. | $34.49 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $34.28 | 2025 | Provenge |
| Emd Serono, INC. | $30.23 | 2020 | |
| Jazz Pharmaceuticals INC. | $29.98 | 2021 | |
| Incyte Corporation | $27.64 | 2025 | Jakafi, Niktimvo |
| Taiho Oncology, INC. | $27.32 | 2024 | |
| Genzyme Corporation | $19.24 | 2021 | |
| Astellas Pharma US INC | $18.91 | 2019 | |
| Pharmacosmos Therapeutics INC. | $18.80 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.54 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.09 | 2021 | |
| Abbvie INC. | $13.72 | 2021 | |
| Beigene USA, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.